ALNY

Alnylam Pharmaceuticals
D

ALNY

285.83
USD
-3.52
(-1.22%)
مفتوح الان
حجم التداول
1,331
الربح لكل سهم
-0
العائد الربحي
-
P/E
-136
حجم السوق
37,235,013,389
أصول ذات صلة
AMGN
AMGN
-1.29
(-0.47%)
271.89 USD
A
ARWR
-0.210
(-1.36%)
15.180 USD
BIIB
BIIB
-2.160
(-1.71%)
124.130 USD
C
CRSP
-0.825
(-2.19%)
36.785 USD
E
EDIT
-0.07500
(-4.63%)
1.54500 USD
GILD
GILD
-0.360
(-0.34%)
106.360 USD
I
IONS
-0.315
(-0.95%)
32.950 USD
REGN
REGN
-8.98
(-1.51%)
587.67 USD
S
SRPT
-0.660
(-1.70%)
38.140 USD
VRTX
VRTX
-2.08
(-0.48%)
432.36 USD
المزيد
الأخبار المقالات

العنوان: Alnylam Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.